Cytokinetics (CYTK) Expected to Announce Earnings on Tuesday

Cytokinetics (NASDAQ:CYTK) will likely be releasing its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of ($1.48) per share and revenue of $8.0230 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Cytokinetics Stock Performance

Shares of NASDAQ CYTK opened at $66.26 on Tuesday. The business’s 50-day simple moving average is $63.39 and its 200-day simple moving average is $56.96. Cytokinetics has a 52 week low of $29.31 and a 52 week high of $70.98. The firm has a market cap of $8.10 billion, a price-to-earnings ratio of -10.53 and a beta of 0.54.

Insiders Place Their Bets

In other news, EVP Fady Ibraham Malik sold 2,200 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total transaction of $134,728.00. Following the sale, the executive vice president directly owned 138,552 shares in the company, valued at approximately $8,484,924.48. The trade was a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Wendell Wierenga sold 20,000 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $66.14, for a total value of $1,322,800.00. Following the completion of the transaction, the director directly owned 32,444 shares of the company’s stock, valued at approximately $2,145,846.16. This trade represents a 38.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 156,385 shares of company stock worth $10,140,808. 3.40% of the stock is currently owned by company insiders.

Institutional Trading of Cytokinetics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC lifted its stake in Cytokinetics by 723.7% during the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 673 shares during the period. Kestra Advisory Services LLC bought a new position in shares of Cytokinetics during the fourth quarter valued at $29,000. Quarry LP acquired a new stake in shares of Cytokinetics in the 3rd quarter valued at $30,000. Advisory Services Network LLC bought a new stake in shares of Cytokinetics in the 3rd quarter worth about $32,000. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of Cytokinetics by 46.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 171 shares during the last quarter.

Wall Street Analyst Weigh In

CYTK has been the subject of several recent analyst reports. B. Riley Financial upped their price objective on shares of Cytokinetics from $90.00 to $108.00 and gave the stock a “buy” rating in a report on Wednesday, January 21st. Truist Financial upped their price target on shares of Cytokinetics from $84.00 to $92.00 and gave the company a “buy” rating in a report on Tuesday, February 3rd. Citizens Jmp lifted their price objective on Cytokinetics from $78.00 to $88.00 and gave the stock a “market outperform” rating in a research note on Monday, December 22nd. Royal Bank Of Canada restated an “outperform” rating and set a $95.00 target price on shares of Cytokinetics in a research note on Wednesday, January 21st. Finally, The Goldman Sachs Group set a $95.00 price target on Cytokinetics and gave the stock a “buy” rating in a research report on Thursday, December 18th. Seventeen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Cytokinetics has a consensus rating of “Moderate Buy” and an average target price of $87.42.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.